Leukemia News

Patients with cancer who resided in low-income and rural areas appeared at higher risk for suicide than those in high-income and urban areas, according to a retrospective, population-based study in JAMA Network Open.

The FDA granted fast track designation to CYNK-001 for the treatment of adults with relapsed or refractory acute myeloid leukemia.

In the last two decades, the approval of multiple tyrosine kinase inhibitors for chronic myeloid leukemia has vastly improved the treatment landscape for patients.

Patients with blood cancer appeared at greater risk for severe and life-threatening COVID-19 illness than healthy individuals and did not always achieve optimal protection from vaccination, according to a registry-based study in Blood.

The FDA granted orphan drug designation to NKX101 for treatment of acute myeloid leukemia.

Early clinical trials for the first chimeric antigen receptor T-cell therapies mandated recipients receive rigorous post-treatment monitoring, often requiring inpatient admittance lasting anywhere from 2 to 4 weeks.

Healio provided comprehensive coverage of this year’s ASH Annual Meeting and Exposition.

Combining the tyrosine kinase inhibitor dasatinib with prednisone and blinatumomab seemed safe in older patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, researchers reported.

Inotuzumab ozogamicin was well tolerated among patients with acute lymphoblastic leukemia who had undergone allogenic transplantation in a small study.

Ivosidenib or enasidenib in combination with chemotherapy showed promising safety and efficacy profiles for newly diagnosed IDH-mutated acute myeloid leukemia, according to a phase 1 trial presented at ASH Annual Meeting and Exposition.